menu
    • menu

    Company profile for Prota Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments. Prota holds an exclusive license to the proprietary food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures’ Healthcare Fund III) ...
    Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments. Prota holds an exclusive license to the proprietary food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures’ Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Prota TherapeuticsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    c/o FB Rice Reception Level 33, 477 Collins Street Melbourne Vic 3000
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://protatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/prota-therapeutics-pty-ltd/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Prota Therapeutics Wins EAACI Prize for PRT120 Long-Term
    Prota Therapeutics Wins EAACI Prize for PRT120 Long-Term

    16 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-16/prota-therapeutics-announces-prt120-follow-on-study-awarded-eaaci-prize-for-long-term-post-treatment

    PHARMAWEB
    16 Sep 2025
    Share Share
    Prota Publishes Long-Term Peanut Allergy Study In Allergy Journal
    Prota Publishes Long-Term Peanut Allergy Study In Allergy Journal

    14 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/prota-therapeutics-announces-publication-in-allergy-of-long-term-peanut-allergy-study-confirming-clinical-remission-as-the-optimal-treatment-outcome-302222276.html

    PR NEWSWIRE
    14 Aug 2024
    Share Share
    Prota CEO Mimi Tang Honored at BioMelbourne Women in Leadership Awards
    Prota CEO Mimi Tang Honored at BioMelbourne Women in Leadership Awards

    29 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/prota-therapeutics-ceo-mimi-tang-honoured-at-biomelbourne-networks-women-in-leadership-awards-2024-302129874.html

    PR NEWSWIRE
    29 Apr 2024
    Share Share
    Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
    Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

    16 Jan 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=825158&lang=en

    ACCESSWIRE
    16 Jan 2024
    Share Share
    Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate
    Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate

    16 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/prota-therapeutics-achieves-51-percent-peanut-allergy-remission-rate-first-company-to-validate-significant-quality-of-life-improvements-compared-with-standard-care-301547484.html

    PRNEWSWIRE
    16 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search